Veralox Therapeutics develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type one diabetes.
Veralox Therapeutics has raised $24.0M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in June 2023.
Veralox Therapeutics's investors include Alumni Ventures, Sanofi, TEDCO, Hatteras Venture Partners, Sanofi Ventures.
Veralox Therapeutics is headquartered in Frederick, United States.
Veralox Therapeutics develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type one diabetes.
Veralox Therapeutics is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Veralox Therapeutics — Funding & Investors." VCBacked, June 20, 2023, https://www.vcbacked.co/company/veralox-therapeutics. Accessed August 6, 2026.
VCBacked. (2023). Veralox Therapeutics — Funding & Investors. Retrieved August 6, 2026, from https://www.vcbacked.co/company/veralox-therapeutics
{{cite web |title=Veralox Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/veralox-therapeutics |website=VCBacked |access-date=August 6, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated